Abstracts tagged "pregnancy"

Abstract Number: 1072 • 2014 ACR/ARHP Annual Meeting
Sex Ratio of Offspring Born to Women with Lupus and Rheumatoid Arthritis
Elizabeth V. Arkema¹, Johan Askling¹, Jane Salmon² and Julia F Simard³, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA
Background/Purpose: Women with SLE are at increased risk for pregnancy complications and specific autoantibodies may result in preferential loss of female offspring. Studies on the…
Abstract Number: 2041 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women Exposed To Golimumab
Amy G. Lau¹, Michael Clark¹, Diane D. Harrison¹, Anja Geldhof², Riikka Nissinen² and Marilyn Sanders¹, ¹Janssen Research & Development, LLC., Horsham, PA, ²Janssen Biologics Europe, Leiden, Netherlands
Background/Purpose: Rheumatologic conditions and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing…
Abstract Number: 2042 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women With Rheumatologic Conditions Exposed To Infliximab
Sirisha Kalari¹, Fredrik Granath², Chun-Yuan Guo¹, Diane D. Harrison¹, Gabriella Bröms², Anja Geldhof³, Riikka Nissinen³, Marilyn Sanders¹, Mika Gissler⁴, Lars Pedersen⁵, Henrik Toft Sorensen⁵ and Helle Kieler², ¹Janssen Research & Development, LLC., Horsham, PA, ²Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden, ³Janssen Biologics Europe, Leiden, Netherlands, ⁴Information Department, National Institute for Health and Welfare, Helsinki, Finland, ⁵Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: RA, AS, and PsA are approved indications for infliximab (IFX). In the US, IFX is a pregnancy Category B drug. For RA and some…
Abstract Number: 1330 • 2013 ACR/ARHP Annual Meeting
Prednisone Use Associated With Worse Outcomes In Rheumatoid Arthritis Pregnancies
Prateek Chaudhary¹ and M. E. B. Clowse², ¹Division of Rheumatology, Duke University Medical Center, Durham, NC, ²Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Prior reports suggest that disease activity in rheumatoid arthritis (RA) improves in the setting of pregnancy. However, prior studies report half of patients having…
Abstract Number: 1046 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Incidence Of Influenza Like Illness In Pregnant Women With Rheumatoid Arthritis and Women Without Rheumatoid Arthritis Who Receive An Influenza Vaccination
Yunjun Luo¹, Diana L. Johnson², Ronghui Xu³ and Christina D. Chambers¹, ¹Pediatrics, University of California, San Diego, La Jolla, CA, ²University of California San Diego Department of Pediatrics, La Jolla, CA, ³Family and Preventive Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Influenza infection poses significant risk to pregnant women, therefore it is recommended that all pregnant women be vaccinated. However, it is unknown whether the…
Abstract Number: 433 • 2013 ACR/ARHP Annual Meeting
Retrospective Analysis Of Certolizumab Pegol Use During Pregnancy: Update Of Impact On Birth Outcomes
Megan E. B. Clowse¹, Douglas C. Wolf², Frauke Förger³, John J. Cush⁴, Christian Stach⁵, Gordana Kosutic⁶, Susan Williams⁶, Chidi Maduka⁶ and Uma Mahadevan⁷, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Atlanta Gastroenterology Associates, Atlanta, GA, ³Department of Rheumatology and Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, ⁴Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Raleigh, NC, ⁷UCSF Medical Center, San Francisco, CA
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF approved in 45 countries for the treatment of rheumatoid arthritis (RA) and/or Crohn's disease (CD). An…
Abstract Number: 2466 • 2012 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: The OTIS Autoimmune Diseases in Pregnancy Project
Christina D. Chambers¹, Diana L. Johnson², Yunjun Luo¹, Janina L. Jimenez¹, Nicole Mirrasoul¹, Elizabeth Salas¹, Kenneth Lyons Jones² and OTIS Research Group³, ¹Pediatrics, University of California, San Diego, La Jolla, CA, ²University of California San Diego Department of Pediatrics, La Jolla, CA, ³Pediatrics, La Jolla
Background/Purpose: The fully human, anti-tumor necrosis factor monoclonal antibody, adalimumab (ADA), is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, juvenile…
Abstract Number: 2237 • 2012 ACR/ARHP Annual Meeting
Application and Feasibility of Proposed Systemic Lupus Erythematosus Reproductive Health Care Quality Indicators At a Public Urban Rheumatology Clinic
Itziar Quinzanos¹, Angela Keniston², Joann Zell³, Jinoos Yazdany⁴, Alyssa Nash¹, Rebecca Fransen¹, Jennifer Stichman¹ and Joel M. Hirsh⁵, ¹Dept Medicine, Denver Health Med Ctr, Denver, CO, ²Department of Medicine, Denver Health and Hospital Authority, Denver, CO, ³Medicine, National Jewish Health, Denver, CO, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO
Background/Purpose: Reproductive health quality indicators (QIs) for systemic lupus erythematosus (SLE) have recently been developed: anti-ssA, anti-ssB, and phospholipid antibody (aPL) screening prior to pregnancy;…
Abstract Number: 1730 • 2012 ACR/ARHP Annual Meeting
Antiphosphatidylethanolamine Is Not Associated with Thrombosis or Pregnancy Loss in Systemic Lupus Erythematosus
Ehtisham Akhter¹, Hong Fang², Nathalie Bardin³, Marielle San Marco³ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Hopital de la Conception, Marseille, France
Background/Purpose: Phosphatidylethanolamine, a zwitterionic phospholipid, is a major component of the cell plasma membrane. Phospatidylethanolamine exerts both anticoagulant and procoagulant activities in different conditions. The…
Abstract Number: 1734 • 2012 ACR/ARHP Annual Meeting
Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of 23 Possible Combinations of Antiphospholipid Antibody Specificities
Savino Sciascia¹, Veronica Murru¹, Giovanni Sanna², Dario Roccatello³, Munther A. Khamashta⁴ and Maria Laura Bertolaccini¹, ¹Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ²Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ³Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ⁴Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: The clinical accuracy of testing for antiphospholipid antibody (aPL) both, as individual tests and/or in combination, is still being investigated. We aimed to identify…
Abstract Number: 1735 • 2012 ACR/ARHP Annual Meeting
Independent Validation of the Antiphospholipid Score (aPL-S) for the Diagnosis of Antiphospholipid Syndrome (APS)
Savino Sciascia¹, Maria Laura Bertolaccini¹, Dario Roccatello² and Munther A. Khamashta³, ¹Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ²Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ³Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: The so called “antiphospholipid score (aPL-S)” was recently developed and validated (1). This score was shown to be a useful quantitative index for diagnosing…
Abstract Number: 1423 • 2012 ACR/ARHP Annual Meeting
Vascular Thrombosis and Pregnancy Morbidity in Patients with Systemic Lupus Erythematosus with Positive Antiphospholipid Profile and Thrombocytopenia
Amir Haddad¹, Murray B. Urowitz², Dominique Ibanez² and D. D. Gladman³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The trigger for a thrombotic in patients with antiphospholipid antibodies is unknown. Thrombocytopenia is among the most common clinical manifestations of the Antiphospholipid antibody…
Abstract Number: 380 • 2012 ACR/ARHP Annual Meeting
DMARD and Biologic Use During Pregnancy Among Rheumatoid and Psoriatic Arthritis Patients in the Corrona Registry
John J. Cush¹, George Reed², Katherine C. Saunders³, Joel M. Kremer⁴, Jeffrey D. Greenberg⁵ and Arthur Kavanaugh⁶, ¹Baylor Research Institute, Dallas, TX, ²Division of Behavioral and Preventive Medicine, University of Massachusetts Medical School, Worcester, MA, ³Corrona, LLC., Southborough, MA, ⁴Center for Rheumatology, Albany Medical College, Albany, NY, ⁵Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ⁶UCSD School of Medicine, La Jolla, CA
Background/Purpose: CORRONA is a nationwide longitudinal disease-based registry that includes 32875 rheumatoid (RA) and 5462 psoriatic arthritis (PsA) patients. We sought to ascertain the frequency…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].